Abstract Treatment with immune checkpoint inhibitors targeting programmed cell death
protein 1 (PD-1) or its ligand (PD-L1) can generate durable responses in various cancer …

It is obvious that tumor cells have developed a number of strategies to escape immune
surveillance including an altered expression of various immune checkpoints, such as the …

Background Despite the efficacy of immune checkpoint inhibitors (ICIs) only the 20–30% of
treated patients present long term benefits. The metabolic changes occurring in the gut …

Background We aimed to assess if quantitative radiomic features can predict programmed
death ligand 1 (PD‐L1) expression in advanced stage lung adenocarcinoma. Methods This …

The diagnostic work-up for non-small cell lung cancer (NSCLC) requires biomarker testing
to guide therapy choices. This article is the second of a two-part series. In Part 1, we …

Objectives To characterize the safety, tolerability, and anti-tumor activity of cemiplimab as
monotherapy or in combination with hypofractionated radiation therapy (hfRT) in patients …

In recent years, the evolution of treatments has made it possible to significantly improve the
outcomes of patients with non-small cell lung cancer (NSCLC). In particular, while molecular …

Background: The immune infiltrate plays an important part in testicular germ cell tumors, but
it remains scarcely studied. We aimed at thoroughly characterizing the immune infiltrate and …

Advanced diagnostics are enabling cancer treatments to become increasingly tailored to the
individual through developments in immunotherapies and targeted therapies. However, long …

Simple Summary The biological behavior of Pituitary Neuroendocrine Tumors (PitNET)
remains unclear. Many efforts have been performed in order to clarify this point. The …